Purdue preps bankruptcy as opioid settlement bid stumbles

pharmaphorum | September 05, 2019

Purdue preps bankruptcy as opioid settlement bid stumbles
Purdue Pharma is reported to be preparing to file for bankruptcy amid resistance to its $10-$12 billion offer to settle lawsuits related to the opioid crisis. Several states and cities have reportedly already rejected its settlement bid, according to news agency Reuters, and Purdue is now gearing up for a Chapter 11 submission before the end of this month while it waits for the final verdict on its offer. At the same time Mallinckrodt – another company embroiled in the thousands of pending lawsuits claiming pharma companies fuelled the opioid epidemic by encouraging over-prescribing of the drugs – is also eyeing bankruptcy protection, says Bloomberg. Purdue, which is the manufacturer of the widely-prescribed opioid painkiller OxyContin (oxycodone), made its settlement offer last month but has to get the deal backed by at least 35 state attorneys to get it accepted, and some states – reportedly New York and Massachusetts – have already rejected it outright. Filing for bankruptcy would stall pending lawsuits, including one due to start next month in Ohio, and could leave plaintiffs trying to tease cash out of the business if it goes into liquidation. Some industry observers have suggested the bankruptcy plan is a tactic by Purdue to try to win over more states to its settlement offer.

Spotlight

The world’s first malaria vaccine in childhood vaccination is being rolled out in 2019 in selected areas of Ghana, Malawi and Kenya, through a pilot programme supported by the World Health Organization.

Related News

Zealand Pharma strengthens executive team with new U.S. leadership

Globe newswire | June 15, 2020

Zealand Pharma, a biotechnology company changing lives with innovative peptide-based medicines, today announced the appointment of Frank Sanders as President of Zealand Pharma U.S. Frank will join Zealand on July 6, 2020. “I am pleased to welcome Frank Sanders to Zealand Pharma, and am confident that he will provide strong and experienced leadership for our U.S. organization,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Frank has more than 25 years of experience within commercial operations. He is well equipped to lead Zealand’s commercial operations to focus on growing existing sales of V-Go and to successfully launch four potential products beginning in 2021.” Frank has extensive experience in leading multidisciplinary operational teams to achieve successfully their growth strategies. He joins Zealand at a critical point in the company’s journey toward commercializing its proprietary products. Frank has worked in both start-up and established companies, where he has built, led and scaled organizations across sales, account management, marketing, pricing and contract strategy, operations, and patient support.

Read More

MEI Pharma to Present at Upcoming Investor Conferences in September

MEI Pharma | September 04, 2020

MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: NETGEAR Orbi Pro WiFi 6 Tri-band Mesh System Brings the Ultimate WiFi Experience to Small Businesses MEI Pharma, Inc. (NASDAQ: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including ME-401, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S. Food and Drug Administration. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information

Read More

PHARMACY MARKET

Fusion Pharmaceuticals has Signed an Agreement to Build a Radiopharmaceutical Manufacturing Facility

Fusion Pharmaceuticals | June 03, 2021

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines; today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University, to build a 27,000 square foot Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility. The facility, to be made by McMaster and equipped and validated by Fusion, will be designed to support the manufacturing of the Company's growing pipeline of targeted alpha therapies (TATs). Fusion expects the manufacturing facility will be operational by early 2024. "Manufacturing and supply chain are critical components of radiopharmaceutical development and commercialization, and with Fusion's expertise, we believe we are well-positioned to create a facility to scale production in support of our growing pipeline and development collaborations," said Fusion Chief executive officer John Valliant, Ph.D. "We will continue to prioritize manufacturing and supply chain infrastructure in our long-term plans, and this facility is an important milestone in executing those plans. The location of the facility, adjacent to our internal research organization and a world-class University that specializes in medical isotope research and training, enables us to efficiently advance new TATs and hire top-tier talent to support our leading portfolio of radiopharmaceuticals." In conjunction with the execution of the lease agreement, Fusion has entered into a services agreement with its long-time partner, the Centre for Probe Development and Commercialization (CPDC), to provide services relating to certain aspects of the validation of this new manufacturing facility. About Fusion Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules to deliver the alpha-emitting payloads to tumors selectively.

Read More

Spotlight

The world’s first malaria vaccine in childhood vaccination is being rolled out in 2019 in selected areas of Ghana, Malawi and Kenya, through a pilot programme supported by the World Health Organization.